反应详情

Following the procedure as described in EXAMPLE 13 and making non-critical variations using 1′-(4-hydroxybenzyl)-5,6-dihydrospiro[benzo[1,2-b:5,4-b′]difuran-3,3′-indol]-2′(1′H)-one to replace 1′-(3-hydroxybenzyl)-5,6-dihydrospiro[benzo[1,2-b:5,4-b′]difuran-3,3′-indol]-2′(1′H)-one, 2-{4-[(2′-oxo-5,6-dihydrospiro[benzo[1,2-b:5,4-b′]difuran-3,3′-indol]-1′(2′H)-yl)methyl]phenoxy}acetamide was obtained (81%) as a colorless solid: mp 215-216° C.; 1H NMR (300 MHz, CDCl3) δ 7.35-7.29 (m, 2H), 7.25-7.14 (m, 2H), 7.06-6.99 (m, 1H), 6.93-6.87 (m, 2H), 6.83-6.78 (m, 1H), 6.52 (br s, 1H), 6.46 (s, 1H), 6.43 (s, 1H), 5.67 (br s, 1H), 5.04-4.95 (m, 2H), 4.85-4.76 (m, 1H), 4.73-4.66 (m, 1H), 4.59-4.50 (m, 2H), 4.48 (s, 2H), 3.10-2.90 (m, 2H); 13C NMR (75 MHz, CDCl3) δ 177.9, 170.7, 161.8, 160.3, 156.7, 142.0, 132.7, 129.6, 129.0, 128.6, 123.9, 123.4, 120.1, 119.9, 118.8, 115.0, 109.1, 93.2, 80.6, 72.4, 67.1, 57.7, 43.4, 29.0; MS (ES+) m/z 443.0 (M+1).